Tarsus Pharmaceuticals, Inc. (NASDAQ:TARS – Get Rating) CEO Bobak R. Azamian sold 8,000 shares of the company’s stock in a transaction dated Wednesday, March 15th. The shares were sold at an average price of $13.79, for a total transaction of $110,320.00. Following the completion of the transaction, the chief executive officer now owns 1,080,536 shares in the company, valued at $14,900,591.44. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link.
Tarsus Pharmaceuticals Stock Down 5.0 %
Shares of Tarsus Pharmaceuticals stock opened at $12.75 on Friday. The company has a current ratio of 16.40, a quick ratio of 16.40 and a debt-to-equity ratio of 0.10. Tarsus Pharmaceuticals, Inc. has a 12-month low of $10.80 and a 12-month high of $19.66. The firm’s 50-day moving average price is $15.07 and its two-hundred day moving average price is $15.88.
Wall Street Analyst Weigh In
Separately, HC Wainwright restated a “buy” rating and issued a $40.00 price target on shares of Tarsus Pharmaceuticals in a research note on Wednesday.
Institutional Investors Weigh In On Tarsus Pharmaceuticals
About Tarsus Pharmaceuticals
Tarsus Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, focuses on the development and commercialization of novel therapeutic candidates for ophthalmic conditions. Its lead product candidate is TP-03, a novel therapeutic that is in Phase III for the treatment of blepharitis caused by the infestation of Demodex mites, as well as to treat meibomian gland disease.
- Get a free copy of the StockNews.com research report on Tarsus Pharmaceuticals (TARS)
- MarketBeat Week in Review – 3/13 – 3/17
- This Small Tech With Big Growth Prospects Is Nearing A Buy Point
- Don’t Chase FedEx Higher, Wait For The Pullback
- 3 Stocks For A Defensive Tech Portfolio
- Milk the Dividends on These 3 Cash Cows
Receive News & Ratings for Tarsus Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Tarsus Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.